Synthetic Vaccines: Test of Concepts and Application to Rift Valley Fever Virus. Phase 1.
Abstract
Use of synthetic peptides, comprising both B and T cell determinants, is being considered a viable approach to vaccine development. We explored several aspects this strategy employing Rift Valley fever virus (RVFV) as the study model. The immunogenicity of synthetic peptides representing several previously identified cell antigenic determinants on the G2 glycoprotein of RVFV was evaluated in several strains of mice differing in H-2 haplotype. Of three B cell antigenic determinants studied, we established two of them to be pure B cell sites (Bl, B3) and one (B2) to additionally possess Th activity with an apparent H-2k restriction. we showed mixing B with known Th peptides was not sufficient to confer immunogenicity on a nonimmunogenic B peptide. Rather, the B and Th determinants must be covalently associated, and preferably, co-synthesized as a single peptide. Finally, we demonstrated we could successfully predict and identify determinants from the primary sequence of glycoprotein G2 capable of enhancing the immunogenicity of the nonimmunogenic Bl peptide. These data provide the first description of putative Th determinants for a phlebovirus. Six such determinants were identified in this Phase I investigation. Through these studies, we demonstrated our technological Synthetic vaccines, Synthetic peptides, B Cell epitopes, T cell epitopes, Immunogenicity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 02, 1990
- Accession Number
- ADB170663
Entities
People
- Marc S. Collett
Organizations
- AstraZeneca (United States)